IBEC-IRB Barcelona joint seminar: Erik Sahai

Imaging therapy response and failure

Many tumors show an initial response to targeted therapies before genetic resistance emerges, however little is known about how tumor cells tolerate therapy before genetic resistance dominates. We present data that shows how the ECM generates a ‘safe haven’ in which melanoma cells can tolerate targeted therapy. This supports the population of cancer cells from which genetically resistance emerges. We are now studying the emergence of resistant clones and clonal competition in the context of ‘safe havens’. Finally, we present analysis of organ specific responses to targeted therapy in melanoma.

Share this...

Facebook

Pinterest

Twitter

Linkedin